Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer

被引:70
作者
Tas, F [1 ]
Duranyildiz, D [1 ]
Argon, A [1 ]
Oguz, H [1 ]
Camlica, H [1 ]
Yasasever, V [1 ]
Topuz, E [1 ]
机构
[1] Istanbul Univ, Inst Oncol, TR-34390 Istanbul, Turkey
关键词
non-small cell lung cancer; IL-6; CRP; leptin; TNF-alpha;
D O I
10.1385/MO:22:4:353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we aimed to investigate the diagnostic and prognostic roles and the effects of chemotherapy of serum proinflammatory cytolcines consisting of IL-6, TNF-alpha, CRP, and leptin levels in patients with advanced-stage non-small cell lung cancer. Twenty-eight patients newly diagnosed of non-surgical advanced non-small cell lung cancer and 15 healthy controls were included. All patients with good performance status were treated with combination therapy consisting of cisplatin plus vinorelbine chemotherapy. Blood samples were obtained in fasting conditions before chemotherapy first and after two cycles of chemotherapy. IL-6 and TNF-alpha immunoassays employ the quantitative sandwich enzyme immunoassay technique. Leptin (Sandwich) ELISA is a solid-phase enzyme-linked immunosorbent assay based on the sandwich principle. CRP is a photometric immunoturbidimetric test. Most of the patients were elderly, male predominance, good performance status, and no or less than 10% weight loss. Higher serum TNF-alpha (p < 0.001) and CRP (p < 0.001), and lower leptin (p = 0.021) levels in patients than in controls. Serum IL-6 cytokine (p = 0.693) levels were not significantly different. No statistically significant relationships between investigated serum parameters and various characteristics of patient and disease. Likewise, serum levels of leptin, IL-6, TNF-alpha, and CRP were all similar in lung cancer patients independently from severity of weight loss (p > 0.05). A direct relationship was found between serum IL-6 and TNF-alpha levels (r = 0.530, p = 0.004). We found that both serum leptin (p = 0.046) and IL-6 (p = 0.002) levels were decreased owing to the chemotherapy effect independently from chemotherapy response. However, serum TNF-alpha and CRP levels were not changed by the chemotherapy effect. The stage of the disease, serum LDH levels, performance status, and responsiveness to chemotherapy yielded prognostic value. Only serum IL-6 levels out of the parameters showed a trend (p = 0.06) related to a worse prognosis.
引用
收藏
页码:353 / 358
页数:6
相关论文
共 27 条
[1]   Leptin role in advanced lung cancer.: A mediator of the acute phase response or a marker of the status of nutrition? [J].
Alemán, MR ;
Santolaria, F ;
Batista, N ;
de la Vega, MJ ;
González-Reimers, E ;
Milena, A ;
Llanos, M ;
Gómez-Sirvent, JL .
CYTOKINE, 2002, 19 (01) :21-26
[2]   Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis [J].
Alexandrakis, MG ;
Passam, FH ;
Perisinakis, K ;
Ganotakis, E ;
Margantinis, G ;
Kyriakou, DS ;
Bouros, D .
RESPIRATORY MEDICINE, 2002, 96 (08) :553-558
[3]   Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer [J].
Aljada, IS ;
Ramnath, N ;
Donohue, K ;
Harvey, S ;
Brooks, JJ ;
Wiseman, SM ;
Khoury, T ;
Loewen, G ;
Slocum, HK ;
Anderson, TM ;
Bepler, G ;
Tan, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3218-3229
[4]   The host-tumor immune conflict: from immunosuppression to resistance and destruction [J].
Chouaib, S ;
AsselinPaturel, C ;
MamiChouaib, F ;
Caignard, A ;
Blay, JY .
IMMUNOLOGY TODAY, 1997, 18 (10) :493-497
[5]  
De Vita F, 1998, J EXP CLIN CANC RES, V17, P413
[6]  
DelPrete G, 1996, T-CELL SUBSETS AND CYTOKINES INTERPLAY IN INFECTIOUS DISEASES, P18
[7]  
DENBREKEL AJS, 1997, BRIT J CANCER, V76, P1630
[8]   Proinflammatory cytokines [J].
Dinarello, CA .
CHEST, 2000, 118 (02) :503-508
[9]   Novel targets for lung cancer therapy: Part II [J].
Dy, GK ;
Adjei, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :3016-3028
[10]   Preoperative chemotherapy increases cytokine production after lung cancer surgery [J].
Endo, S ;
Sato, Y ;
Hasegawa, T ;
Tetsuka, K ;
Otani, S ;
Saito, N ;
Tezuka, Y ;
Sohara, Y .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 26 (04) :787-791